Mixed trend on the daily chart: above its 200-day average, below its 50-day · 50-day above the 200-day · SuperTrend up since Aug 3 · below the Ichimoku cloud · RSI 43 · MACD below its signal
| 17.96 | 52-week high | +332.77% |
| 5.33 | Previous month high | +28.43% |
| 4.64 | Previous week high | +11.81% |
| 4.57 | R3 (classic) | +10.01% |
| 4.42 | R2 (classic) | +6.57% |
| 4.29 | R1 (classic) | +3.29% |
| 4.28 | Previous day high | +3.13% |
| 4.15 | Price now | |
| 4.14 | Pivot | −0.15% |
| 4.01 | S1 (classic) | −3.44% |
| 4.00 | Previous day low | −3.59% |
| 3.96 | Previous week low | −4.58% |
| 3.86 | S2 (classic) | −6.88% |
| 3.77 | Previous month low | −9.16% |
| 3.73 | S3 (classic) | −10.16% |
| 2.00 | 52-week low | −51.81% |
None of the 29 investors followed here reported a position in UPC in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 16.0 | -38.5 | 1.1 | 17.4 | 8.4 | 74.3 | -48.2 | 44.9 | -6.1 | -3.5 | +8.9% | ||
| 2025 | -33.6 | -68.4 | -19.9 | 16.6 | -1.7 | -20.2 | -5.7 | 0.3 | 18.4 | 12.4 | -16.5 | -3.3 | −84.4% |
| 2024 | 4.0 | -10.0 | 16.5 | 10.0 | 21.3 | -14.8 | 48.2 | -11.9 | -92.5 | 7.8 | -54.9 | -65.7 | −98.0% |
| 2023 | -41.4 | -29.4 | -3.0 | -17.4 | 20.6 | -37.9 | -3.7 | -32.7 | -32.1 | 17.9 | -24.6 | 137.9 | −76.9% |
| 2022 | -14.4 | -12.1 | 2.8 | -5.9 | -7.6 | -42.9 | 1.0 | -19.6 | 10.8 | 92.0 | 66.8 | -19.9 | −11.3% |
| 2021 | -8.2 | -12.8 | -1.2 | -25.2 | -2.1 | 6.5 | -8.1 | -4.8 | -24.3 | −59.2% |
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| May 6, 2026 | Lai GangChief Executive Officer | Stock Award(Grant) at price 0.00 per share. | 84.5K | — |
No member of Congress has disclosed a UPC trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
No analyst coverage for this instrument.
Universe Pharmaceuticals INC, through its subsidiaries, engages in the manufacturing, marketing, distribution, and sales of traditional Chinese medicine derivative products in China. The company offers products for the treatment and relief of common chronic health conditions in the elderly for physical wellness and longevity; and cold and flu medications. It also provides guben yanling, shenrong weisheng, and quanlu pill; yangxue danggui and qiangli pipa syrup; wuzi yanzong oral, fengtong medicinal, shenrong medicinal, qishe medicinal, fengshitong medicinal, and shiquan dabu medicinal liquor; paracetamol granule for children; and isatis root granule. In addition, the company distributes and sells third-party products, including biomedical drugs, medical instruments, traditional Chinese medicine pieces, and dietary supplements. It primarily serves pharmaceutical companies, hospitals, clinics, and drugstore chains. The company was founded in 1998 and is headquartered in Ji'An, China. Universe Pharmaceuticals INC is a subsidiary of Sununion Holding Group Limited.